Pentasa and Uip - a phase IV clinical study of FDA data

Summary:

Uip is reported as a side effect among people who take Pentasa (mesalamine), especially for people who are male, 60+ old, have been taking the drug for 10+ years also take Remicade, and have Cytomegalovirus infection.

The phase IV clinical study analyzes which people have Uip when taking Pentasa. It is created by eHealthMe based on reports of 22,797 people who have side effects when taking Pentasa from the FDA, and is updated regularly.

What is Pentasa?

Pentasa has active ingredients of mesalamine. It is often used in crohn's disease. eHealthMe is studying from 23,325 Pentasa users. Check the latest studies of Pentasa.

What is Uip?

Uip (usual interstitial pneumonia (uip) is a form of lung disease characterized by progressive scarring of both lungs) is found to be associated with 1,657 drugs and 2,248 conditions by eHealthMe. Check the latest studies of Uip.

On Nov, 14, 2025

22,797 people reported to have side effects when taking Pentasa.
Among them, 32 people (0.14%) have Uip.

Among these 32 people:

How long have people been on Pentasa when they have Uip? *

What is the gender of people who have Uip when taking Pentasa? *

female: 29.03 %
male: 70.97 %

What is the age of people who have Uip when taking Pentasa? *

What are other drugs people take besides Pentasa? *

What are other side effects people have besides Uip? *

Pneumonia: 6 people, 18.75%
Chest Pain: 3 people, 9.38%
Weight Decreased: 3 people, 9.38%
Weakness: 3 people, 9.38%
Interstitial Lung Disease: 3 people, 9.38%
Drug Hypersensitivity: 3 people, 9.38%
Rib Fracture: 3 people, 9.38%
Pneumocystis Carinii Pneumonia (pneumonia occurring in infants or in persons with impaired immune systems): 3 people, 9.38%
Lung Neoplasm Malignant (cancer tumour of lung): 3 people, 9.38%
Haematochezia (passage of stools containing blood): 2 people, 6.25%

What are the existing conditions these people have? *

Stress And Anxiety: 1 person, 3.12%
Pain: 1 person, 3.12%
Insomnia (sleeplessness): 1 person, 3.12%
Infection: 1 person, 3.12%
Hyperlipidaemia (presence of excess lipids in the blood): 1 person, 3.12%
High Blood Pressure: 1 person, 3.12%
High Blood Cholesterol: 1 person, 3.12%
Heart Attack: 1 person, 3.12%
Gastritis (inflammation of stomach): 1 person, 3.12%
Cytomegalovirus Infection: 1 person, 3.12%

* Approximation only. Some reports may have incomplete information.

Do you take Pentasa and have Uip?

- Check whether Uip is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Pentasa:

Pentasa (23,325 reports)

Uip treatments and more:

Uip (79,192 reports)

Browse all side effects of Pentasa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Uip:

Uip (1,657 drugs)

Browse all the conditions that are associated with Uip:

Uip (2,248 conditions)

Drugs similar to Pentasa and Uip :

Related publications that referenced our studies

Jacobsson H, Eriksen J, Karlén P, "Mesalazine-induced renal calculi", The American journal of case reports, 2015 Jan .
Jacobsson H, Eriksen J, Karlén P, "Mesalazine-induced renal calculi", The American journal of case reports, 2015 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on mesalamine (the active ingredients of Pentasa) and Pentasa (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.